Heart failure prevalence, medications, and outcomes in transcatheter aortic valve interventions: the real-world analysis

Q: What is the clinical evidence from this study?

Study design: Observational. Population: Transcatheter aortic valve interventions (n=37490). Intervention: Transcatheter aortic valve interventions (TAVI). Primary outcome: Composite of heart failure hospitalization and mortality at one year (95% CI 15.2-16.0).

Q: What does this research mean for the field?

Patients undergoing transcatheter aortic valve intervention exhibit a high burden of heart failure and a substantial residual risk of hospitalization and mortality, while post-procedure heart failure medical therapies remain markedly underprescribed. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

Елена Суркова; Matthew Arnold; Gábor Földes; Judith Hartleib‐Geschwindner

doi:10.2459/jcm.0000000000001899

July 31, 2026Journal of Cardiovascular MedicineOpen Access

Heart failure prevalence, medications, and outcomes in transcatheter aortic valve interventions: the real-world analysis

View Full Paper

Ask AI

Bookmark

Share

Why the study?

Despite successful TAVI procedures, a residual risk of heart failure hospitalization persists and HF therapies are underused in this population.

What is the prevalence of heart failure, use of HF medications, and risk of HF hospitalization and mortality in patients undergoing transcatheter aortic valve interventions?

Key Points

To evaluate the prevalence of heart failure, patterns of heart failure medication use, and clinical outcomes among patients undergoing transcatheter aortic valve interventions in real-world practice.
Retrospective analysis of N=37,490 patients undergoing transcatheter aortic valve intervention identified from Optum's de-identified Clinformatics Data Mart.
Tracked pre-procedural heart failure diagnoses during the preceding year, post-procedural prescription rates, and clinical endpoints over a two-year follow-up.
A heart failure diagnosis was present in 21,283 (56.9%) patients within the year prior to transcatheter aortic valve intervention.
The cumulative risk for the composite outcome of heart failure hospitalization and mortality was 15.6% (95% CI, 15.2–16.0) at one year and 25.4% (95% CI, 24.8–25.9) at two years.
Prescription rates for heart failure medications remained low following the procedure despite the substantial residual risk of clinical deterioration.

Study Design

Type

Observational (n=37,490)

Structured PICO

What is the prevalence of heart failure, use of HF medications, and risk of HF hospitalization and mortality in patients undergoing transcatheter aortic valve interventions?

P

Population

37,490 patients from a real-world database undergoing transcatheter aortic valve interventions, followed for up to 2 years.

E

Exposure

Transcatheter aortic valve interventions (TAVI)

O

Outcome

Composite of HF hospitalization and mortality at one and two yearscomposite

Implication

A high proportion of patients undergoing TAVI have pre-existing heart failure and face significant residual risks of HF hospitalization and mortality, yet HF therapies remain underutilized post-procedure.

Abstract

BACKGROUND: Despite successful transcatheter aortic valve interventions (TAVIs), a residual risk of heart failure (HF) hospitalization persists. RESULTS: A total of 37 490 patients from Optum's de-identified Clinformatics Data Mart were included. HF diagnosis was recorded in 21 283 (56.9%) patients during a year before TAVI. One-/two-year risks for a composite of HF hospitalization and mortality were 15.6% [95% confidence interval (CI), 15.2-16.0]/25.4% (95% CI, 24.8-25.9). Post-TAVI, HF medication prescriptions remained low. MAJOR FINDINGS: HF burden among TAVI recipients is high and HF therapies are underused. Persistent residual risks highlight the need for future clinical trials investigating a role of more aggressive medical management after TAVI.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Суркова et al. (2026) conducted an observational in Transcatheter aortic valve interventions (n=37,490). Transcatheter aortic valve interventions (TAVI) was evaluated on Composite of heart failure hospitalization and mortality at one year (95% CI 15.2-16.0).

synapsesocial.com/papers/6ad0fcf33afa093ea9ad010d https://doi.org/10.2459/jcm.0000000000001899